TY - JOUR
T1 - Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers
AU - Ferrucci, Luigi
AU - Cherubini, Antonio
AU - Bandinelli, Stefania
AU - Bartali, Benedetta
AU - Corsi, Annamaria
AU - Lauretani, Fulvio
AU - Martin, Antonio
AU - Andres-Lacueva, Cristina
AU - Senin, Umberto
AU - Guralnik, Jack M.
PY - 2006/2
Y1 - 2006/2
N2 - Aims: Persons with high intake of polyunsaturated fatty acids (PUFAs) have lower cardiovascular morbidity and mortality. The protective effect of PUFAs is mediated by multiple mechanisms, including their antiinflammatory properties. The association of physiological PUFA levels with pro- and antiinflammatory markers has not been established. Methods and Results: In 1123 persons (aged 20-98 yr), we examined the relationship between relative concentration of fatty acids in fasting plasma and level of inflammatory markers. Adjusting for age, sex, and major confounders, lower arachidonic and docosahexaenoic acids were associated with significantly higher IL-6 and IL-1ra and significantly lower TGFβ. Lower α-linolenic acid was associated with higher C-reactive protein and IL-1ra, and lower eicosapentaenoic acid was associated with higher IL-6 and lower TGFβ. Lower docosahexaenoic acid was strongly associated with lower IL-10. Total n-3 fatty acids were associated with lower IL-6 (P = 0.005), IL-1ra (P = 0.004), and TNFα (P = 0.040) and higher soluble IL-6r (P <0.001), IL-10 (P = 0.024), and TGFβ (P = 0.0012). Lower n-6 fatty acid levels were significantly associated with higher IL-1ra (P = 0.026) and lower TGFβ (P = 0.014). The n-6 to n-3 ratio was a strong, negative correlate of IL-10. Findings were similar in participants free of cardiovascular diseases and after excluding lipids from covariates. Conclusions: In this community-based sample, PUFAs, and especially total n-3 fatty acids, were independently associated with lower levels of proinflammatory markers (IL-6, IL-1ra, TNFα, C-reactive protein) and higher levels of antiinflammatory markers (soluble IL-6r, IL-10, TGFβ) independent of confounders. Our findings support the notion that n-3 fatty acids may be beneficial in patients affected by diseases characterized by active inflammation.
AB - Aims: Persons with high intake of polyunsaturated fatty acids (PUFAs) have lower cardiovascular morbidity and mortality. The protective effect of PUFAs is mediated by multiple mechanisms, including their antiinflammatory properties. The association of physiological PUFA levels with pro- and antiinflammatory markers has not been established. Methods and Results: In 1123 persons (aged 20-98 yr), we examined the relationship between relative concentration of fatty acids in fasting plasma and level of inflammatory markers. Adjusting for age, sex, and major confounders, lower arachidonic and docosahexaenoic acids were associated with significantly higher IL-6 and IL-1ra and significantly lower TGFβ. Lower α-linolenic acid was associated with higher C-reactive protein and IL-1ra, and lower eicosapentaenoic acid was associated with higher IL-6 and lower TGFβ. Lower docosahexaenoic acid was strongly associated with lower IL-10. Total n-3 fatty acids were associated with lower IL-6 (P = 0.005), IL-1ra (P = 0.004), and TNFα (P = 0.040) and higher soluble IL-6r (P <0.001), IL-10 (P = 0.024), and TGFβ (P = 0.0012). Lower n-6 fatty acid levels were significantly associated with higher IL-1ra (P = 0.026) and lower TGFβ (P = 0.014). The n-6 to n-3 ratio was a strong, negative correlate of IL-10. Findings were similar in participants free of cardiovascular diseases and after excluding lipids from covariates. Conclusions: In this community-based sample, PUFAs, and especially total n-3 fatty acids, were independently associated with lower levels of proinflammatory markers (IL-6, IL-1ra, TNFα, C-reactive protein) and higher levels of antiinflammatory markers (soluble IL-6r, IL-10, TGFβ) independent of confounders. Our findings support the notion that n-3 fatty acids may be beneficial in patients affected by diseases characterized by active inflammation.
UR - http://www.scopus.com/inward/record.url?scp=32544451437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32544451437&partnerID=8YFLogxK
U2 - 10.1210/jc.2005-1303
DO - 10.1210/jc.2005-1303
M3 - Article
C2 - 16234304
AN - SCOPUS:32544451437
SN - 0021-972X
VL - 91
SP - 439
EP - 446
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 2
ER -